Clinical trials: Plasma Cell Tumor
Plasma Cell Myeloma
Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma
This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM).
- Trial name
- NCT05918185
- Testing
- Biospecimen Collection, Comprehensive Geriatric Assessment, Electronic Health Record Review
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy
Since the pathophysiology of BIPN still remains unclear, in the present study we are going to assess the development of BIPN in newly diagnosed myeloma patients, based on clinical neurological examination and electrophysiological…
- Trial name
- BIPN (NCT01171443)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Wolfson Medical Center
Multiple Myeloma
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of…
- Trial name
- NCT03126617
- Testing
- Elotuzumab
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment
This study has been designed in order to detect EGFR mutation abundance of tissue and concentration of plasma from Advanced Non-small Cell Lung Cancer during treatment with Tyrosine Kinase Inhibitor (TKI) .Through this experiment…
- Trial name
- NCT02644889
- Volunteers
- 100 people
- Sponsor
- GenoSaber
Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder
Epcoritamab in Previously Treated WM
This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM).
- Trial name
- NCT06510491
- Testing
- Epcoritamab
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Gottfried von Keudell, MD PhD
Multiple Myeloma and Plasma Cell Neoplasm
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00568880
- Testing
- bortezomib, hydroxychloroquine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma, Disease of the Marrow
Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions
Developing an MRI protocol at 1.5 T allowing quantification of the hematopoietic, fatty and trabecular moieties of marrow. An ideal protocol would differentiate red marrow from neoplastic cellular infiltration, and detect loss of…
- Conditions
- Multiple Myeloma, Disease of the Marrow, Osteoporosis
- Trial name
- NCT01880762
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
This phase I trial studies the side effects of NY-ESO-1 TCR engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after melphalan conditioning regimen in treating participants with multiple…
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NYSCT MM (NCT03506802)
- Testing
- 18F-FHBG, Aldesleukin, Cellular Therapy
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this combination works in treating patients with B-cell non-Hodgkin lymphoma that has…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT02281279
- Testing
- rituximab, lenalidomide, romidepsin
- Sponsor
- Mayo Clinic
Multiple Myeloma
Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients
Comparing intermediate-dose CTX (ID-CTX)and G-CSF with rhTPO or without for peripheral blood stem cell mobilization in patients with multiple myeloma, try to find out whether rhTPO combined to ID-CTX + G-CSF could improve the…
- Trial name
- NCT02572596
- Testing
- rhTPO, CTX, -CSF
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wang Guorong
Multiple Myeloma
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Patients with myeloma that has either not responded to previous treatment or has returned after previous treatment will be given a combination of the drugs bendamustine and bortezomib.
- Trial name
- NCT01315873
- Testing
- Bendamustine, Bortezomib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Multiple Myeloma, Primary Plasma Cell Leukemia
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma
- Conditions
- Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
- Trial name
- NCT06140966
- Testing
- Daratumumab, Carfilzomib, Lenalidomide
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma
Study of bb2121 in Multiple Myeloma
Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT02658929
- Testing
- bb2121
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Celgene
Multiple Myeloma
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
This is a Phase 2 study, open-label, 2-cohort, multicenter, national, interventional in patients with newly diagnosed multiple myeloma.
- Trial name
- IFm2022-01 (NCT06353022)
- Testing
- Teclistamab, Talquetamab, Lenalidomide
- Where
- 19 sites in France
- Volunteers
- 103 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma, Newly Diagnosed
KPD Consolidation After ASCT in NDMM Patients
This study aims to evaluate the efficacy and safety of post-transplant consolidation therapy with the KPD regimen (carfilzomib, pomalidomide, and dexamethasone) versus no consolidation, followed by maintenance therapy, in…
- Trial name
- NCT06879379
- Testing
- KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation
- Where
- 3 sites in China
- Volunteers
- 202 people
- Sponsor
- Peking University People's Hospital
Multiple Myeloma, Stem Cell Transplant
Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation
Autologous stem cell transplantation (SCT) is the standard of care for fit multiple myeloma (MM) patients; however, the first 100 days after SCT are marked by extensive life disruptions.
- Trial name
- NCT04589286
- Testing
- Pack Health's Digital Life Coaching (DLC), Electronic Handouts
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery
The treatment of colorectal cancer, in the absence of metastases, is primarily based on surgical removal. Colorectal surgery, which involves resecting part of the intestine and restoring intestinal continuity, carries a risk of…
- Trial name
- POSBIO-CRC (NCT07268846)
- Testing
- Postbiotic
- Where
- Brazil
- Volunteers
- 164 people
- Sponsor
- AC Camargo Cancer Center
Relapsed/Refractory Multiple Myeloma
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM).
- Trial name
- NCT07760454
- Testing
- CT0596
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- UCARsgen Biotech Limited
Multiple Myeloma
A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
Four monthly treatments with pegylated liposomal doxorubicin, thalidomide and dexamethasone for newly diagnosed myeloma patients as induction therapy prior to high dose chemotherapy and autologous stem cell transplant.
- Trial name
- NCT00222105
- Testing
- Doxil, Thalidomide, Dexamethasone
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Immunodeficiency, Immunosuppression
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce…
- Conditions
- Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease
- Trial name
- NCT05655546
- Testing
- Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- Scripps Translational Science Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.